These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36115656)

  • 21. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
    Marquard FE; Jücker M
    Biochem Pharmacol; 2020 Feb; 172():113729. PubMed ID: 31785230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells.
    Sundaramoorthy P; Ramasamy T; Mishra SK; Jeong KY; Yong CS; Kim JO; Kim HM
    Acta Biomater; 2016 Sep; 42():220-231. PubMed ID: 27395829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
    Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
    Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
    Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
    Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial-mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation.
    Zheng Y; Xie L; Xu S; Yan W; Zhang H; Meng Y; Liu J; Wei X
    Mol Cell Biochem; 2021 Nov; 476(11):4031-4044. PubMed ID: 34244973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. cRGDyK modified pH responsive nanoparticles for specific intracellular delivery of doxorubicin.
    Qiu L; Hu Q; Cheng L; Li L; Tian C; Chen W; Chen Q; Hu W; Xu L; Yang J; Cheng L; Chen D
    Acta Biomater; 2016 Jan; 30():285-298. PubMed ID: 26602824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
    Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
    Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. pH-Sensitive nanoparticles as smart carriers for selective intracellular drug delivery to tumor.
    Li XX; Chen J; Shen JM; Zhuang R; Zhang SQ; Zhu ZY; Ma JB
    Int J Pharm; 2018 Jul; 545(1-2):274-285. PubMed ID: 29733971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. pH sensitive peptide functionalized nanoparticles for co-delivery of erlotinib and DAPT to restrict the progress of triple negative breast cancer.
    Wan X; Liu C; Lin Y; Fu J; Lu G; Lu Z
    Drug Deliv; 2019 Dec; 26(1):470-480. PubMed ID: 30957572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miRNA-125b regulates apoptosis of human non-small cell lung cancer via the PI3K/Akt/GSK3β signaling pathway.
    Wang Y; Zhao M; Liu J; Sun Z; Ni J; Liu H
    Oncol Rep; 2017 Sep; 38(3):1715-1723. PubMed ID: 28713974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overcoming chemotherapy resistance using pH-sensitive hollow MnO
    Zhou ZH; Liang SY; Zhao TC; Chen XZ; Cao XK; Qi M; Huang YY; Ju WT; Yang M; Zhu DW; Pang YC; Zhong LP
    J Nanobiotechnology; 2021 May; 19(1):157. PubMed ID: 34039370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Pt(IV) prodrug self-assembled nanoparticles with enhanced blood circulation stability and improved antitumor capacity of oxaliplatin for cancer therapy.
    Fu Y; Kong Y; Li X; Cheng D; Hou Y; Li Y; Li T; Xiao Y; Zhang Q; Rong R
    Drug Deliv; 2023 Dec; 30(1):2171158. PubMed ID: 36744299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone marrow mesenchymal stem cells promote head and neck cancer progression through Periostin-mediated phosphoinositide 3-kinase/Akt/mammalian target of rapamycin.
    Liu C; Feng X; Wang B; Wang X; Wang C; Yu M; Cao G; Wang H
    Cancer Sci; 2018 Mar; 109(3):688-698. PubMed ID: 29284199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erinacine Facilitates the Opening of the Mitochondrial Permeability Transition Pore Through the Inhibition of the PI3K/ Akt/GSK-3β Signaling Pathway in Human Hepatocellular Carcinoma.
    Zhou LJ; Mo YB; Bu X; Wang JJ; Bai J; Zhang JW; Cheng AB; Ma JH; Wang YW; Xie YX
    Cell Physiol Biochem; 2018; 50(3):851-867. PubMed ID: 30355923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enzyme/pH Dual-Responsive Engineered Nanoparticles for Improved Tumor Immuno-Chemotherapy.
    Liu Z; Hao X; Qian J; Zhang H; Bao H; Yang Q; Gu W; Huang X; Zhang Y
    ACS Appl Mater Interfaces; 2024 Mar; 16(10):12951-12964. PubMed ID: 38422377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Canagliflozin, a SGLT-2 inhibitor, relieves ER stress, modulates autophagy and induces apoptosis in irradiated HepG2 cells: Signal transduction between PI3K/AKT/GSK-3β/mTOR and Wnt/β-catenin pathways;
    Abdel-Rafei MK; Thabet NM; Rashed LA; Moustafa EM
    J Cancer Res Ther; 2021; 17(6):1404-1418. PubMed ID: 34916371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Matrix metalloprotein-triggered, cell penetrating peptide-modified star-shaped nanoparticles for tumor targeting and cancer therapy.
    Guo F; Fu Q; Zhou K; Jin C; Wu W; Ji X; Yan Q; Yang Q; Wu D; Li A; Yang G
    J Nanobiotechnology; 2020 Mar; 18(1):48. PubMed ID: 32183823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor microenvironment targeting with dual stimuli-responsive nanoparticles based on small heat shock proteins for antitumor drug delivery.
    Shi K; Wang Y; Zhou X; Gui H; Xu N; Wu S; He C; Zhao Z
    Acta Biomater; 2020 Sep; 114():369-383. PubMed ID: 32688090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer.
    Xie Y; Ren Z; Chen H; Tang H; Zhu M; Lv Z; Bao H; Zhang Y; Liu R; Shen Y; Zheng Y; Miao D; Guo X; Chen H; Wang S; Pei J
    Biomed Pharmacother; 2023 Apr; 160():114304. PubMed ID: 36724638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Capilliposide C Sensitizes Esophageal Squamous Carcinoma Cells to Oxaliplatin by Inducing Apoptosis Through the PI3K/Akt/mTOR Pathway.
    Shen Z; Xu L; Li J; Zhang N
    Med Sci Monit; 2017 May; 23():2096-2103. PubMed ID: 28463955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.